Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inspire Medical Systems ( (INSP) ) has issued an update.
At its April 30, 2026 annual meeting, Inspire Medical Systems’ stockholders approved a key amendment to the company’s certificate of incorporation to phase out its classified board structure, moving to annual elections for all directors beginning with the 2029 annual meeting. The change, formally filed in Delaware on May 1, 2026, is expected to increase board accountability and aligns the company with prevailing corporate governance practices favored by many institutional investors.
Shareholders also elected three Class II directors to terms ending in 2029, ratified Ernst & Young LLP as independent auditor for 2026, and backed executive compensation and an annual say-on-pay frequency. In addition, investors approved amendments to the 2018 Incentive Award Plan and authorized, though ultimately did not require, a potential adjournment of the meeting to secure votes on governance and compensation proposals, signaling broad support for the company’s current strategic and governance framework.
The most recent analyst rating on (INSP) stock is a Hold with a $55.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Spark’s Take on INSP Stock
According to Spark, TipRanks’ AI Analyst, INSP is a Neutral.
The score is driven by strong underlying fundamentals (high growth, improved profitability, strong margins, and a conservative balance sheet), but is meaningfully weighed down by the earnings outlook reset from reimbursement/WISER disruptions and a cautious technical backdrop with the stock below key longer-term moving averages. Valuation is reasonable (P/E ~18.6) but not enough to offset near-term uncertainty.
To see Spark’s full report on INSP stock, click here.
More about Inspire Medical Systems
Inspire Medical Systems, Inc. operates in the medical technology sector, developing and commercializing implantable neurostimulation devices to treat obstructive sleep apnea. The company targets patients who are unable to tolerate continuous positive airway pressure therapy and markets its system primarily through sleep specialists and otolaryngologists in the U.S. and international markets.
Average Trading Volume: 1,150,237
Technical Sentiment Signal: Sell
Current Market Cap: $1.58B
See more insights into INSP stock on TipRanks’ Stock Analysis page.